Thibaut Charrier1,2, Guillaume Passot1,2, Julien Peron3, Christelle Maurice4, Sashka Gocevska5, François Quénet5, Clarisse Eveno6, Marc Pocard6, Diane Goere7, Dominique Elias7, Pablo Ortega-Deballon8, Delphine Vaudoyer1,2, Eddy Cotte1,2, Olivier Glehen9,10. 1. Department of General Surgery, Centre Hospitalier Lyon Sud, Pierre Bénite, France. 2. EMR 3738, Lyon 1 University, Lyon, France. 3. Department of Biostatistics, UMR 5558, Lyon 1 University, Lyon, France. 4. Pôle IMER, Unité de Recherche Clinique, Hospices Civils de Lyon, Lyon, France. 5. Department of Surgery, Centre Val d'Aurelle, Montpellier, France. 6. Department of Surgery, Hôpital Lariboisière, Assistance-Publique, des hôpitaux de Paris, Paris 7 Université Paris Diderot, Paris, France. 7. Department of Surgery, Gustave Roussy, Cancer Campus, Grand Paris, Paris, France. 8. Department of Surgery, Centre Hospitalier Universitaire de Dijon, Dijon, France. 9. Department of General Surgery, Centre Hospitalier Lyon Sud, Pierre Bénite, France. olivier.glehen@chu-lyon.fr. 10. EMR 3738, Lyon 1 University, Lyon, France. olivier.glehen@chu-lyon.fr.
Abstract
BACKGROUND: Treatment of peritoneal carcinomatosis (PC) using cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is recommended as curative treatment for selected patients. Modalities of HIPEC remain heterogeneous and HIPEC using oxaliplatin (HIPEC-Ox) appears to increase the risk of postoperative hemorrhagic complications (HCs). OBJECTIVE: The aim of this study was to assess the risk of HCs after CRS combined with HIPEC-Ox versus other drugs, and to determine predictive factors for HCs after HIPEC-Ox. METHODS: Data from 701 patients included in the National French Registry who were treated with CRS and HIPEC at 24 centers between 1998 and 2007 were used to evaluate the incidence of HCs following HIPEC with or without oxaliplatin. Overall, 771 patients treated with HIPEC-Ox at five French specialty centers were then analyzed to determine factors associated with the occurrence of HCs. RESULTS: The overall incidence of HCs was 9.8 %. When used with HIPEC, oxaliplatin significantly and independently increased the rate of HCs (15.7 vs. 2.6 % for other drugs; p = 0.004, odds ratio 32.4). Among the 771 patients who underwent HIPEC-Ox, HCs occurred in 14.3 % of patients. The only independent risk factor for HCs was an extended PC with a Peritoneal Cancer Index (PCI) >12 (p = 0.040). CONCLUSION: HIPEC-Ox increases the risk of HCs compared with HIPEC with other drugs. The potential oncologic benefit of oxaliplatin and the risk of HCs should be considered in patients with PC who have a high PCI, as well as in at-risk patients.
BACKGROUND: Treatment of peritoneal carcinomatosis (PC) using cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is recommended as curative treatment for selected patients. Modalities of HIPEC remain heterogeneous and HIPEC using oxaliplatin (HIPEC-Ox) appears to increase the risk of postoperative hemorrhagic complications (HCs). OBJECTIVE: The aim of this study was to assess the risk of HCs after CRS combined with HIPEC-Ox versus other drugs, and to determine predictive factors for HCs after HIPEC-Ox. METHODS: Data from 701 patients included in the National French Registry who were treated with CRS and HIPEC at 24 centers between 1998 and 2007 were used to evaluate the incidence of HCs following HIPEC with or without oxaliplatin. Overall, 771 patients treated with HIPEC-Ox at five French specialty centers were then analyzed to determine factors associated with the occurrence of HCs. RESULTS: The overall incidence of HCs was 9.8 %. When used with HIPEC, oxaliplatin significantly and independently increased the rate of HCs (15.7 vs. 2.6 % for other drugs; p = 0.004, odds ratio 32.4). Among the 771 patients who underwent HIPEC-Ox, HCs occurred in 14.3 % of patients. The only independent risk factor for HCs was an extended PC with a Peritoneal Cancer Index (PCI) >12 (p = 0.040). CONCLUSION:HIPEC-Ox increases the risk of HCs compared with HIPEC with other drugs. The potential oncologic benefit of oxaliplatin and the risk of HCs should be considered in patients with PC who have a high PCI, as well as in at-risk patients.